Sign in

Michael Cherney

Managing Director and Senior Equity Research Analyst at Jefferies Financial Group Inc.

Michael Cherney is a Managing Director and Senior Equity Research Analyst at Jefferies Financial Group Inc., specializing in healthcare services and diagnostics coverage. He closely follows major companies such as Quest Diagnostics and DENTSPLY SIRONA, contributing industry insights and in-depth analysis to investors, and actively questioning company leadership on earnings calls. Recognized for his expertise in healthcare equity research, he has maintained a high profile through regular participation in industry events and corporate updates. Cherney has held analyst roles at leading financial firms, including Bank of America before joining Jefferies, and holds FINRA securities licenses applicable to his profession.

Michael Cherney's questions to LABCORP HOLDINGS (LH) leadership

Question · Q3 2025

Michael Cherney from Leerink Partners asked for insights into the strong organic price per mix, particularly how much of this growth is driven by proactive company strategies versus market dynamics, and its sustainability beyond the current year.

Answer

Chairman and CEO Adam Schechter provided context on diagnostics revenue growth, while EVP and CFO Julia Wang explained that the 2.8% organic price mix increase was primarily due to a favorable mix, including a rise in tests per session and the annualization of Invitae. She projected continued mix growth supported by hospital partnerships, an aging population, health and wellness trends, and specialty testing.

Ask follow-up questions

Question · Q3 2025

Michael Cherney inquired about the strong organic price per mix, asking what factors were proactive versus reactive, and how this trend is expected to build beyond the current year.

Answer

Chairman and CEO Adam Schechter highlighted 8.5% diagnostics revenue growth, with 6% organic growth, comprising 3.5% organic volume and 2.8% price mix. EVP and CFO Julia Wang explained that unit price remained relatively flat, with mix growth primarily driven by increased tests per session and the annualization of Invitae. She anticipates continued mix favorability, supported by hospital partnerships, an aging population, and specialty testing.

Ask follow-up questions

Michael Cherney's questions to QUEST DIAGNOSTICS (DGX) leadership

Question · Q3 2025

Michael Cherney asked for clarification on the mix in the quarter, specifically how wellness and specialty testing performance compared to March's long-range plan (LRP) expectations, and their anticipated contribution to overall organic volume and revenue growth.

Answer

CEO Jim Davis indicated that consumer channels, both direct and partnerships, are performing slightly above expectations set in March, driven by strong direct channel growth (30-40% YTD) and momentum from consumer health companies. CFO Sam Samad affirmed that the LRP assumptions from March, including mid-single-digit revenue growth and high-single-digit EPS growth, remain largely intact, with positive trends in utilization and test mix contributing to operating margin.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts